U6-shRNA-GFP AAV (Serotype 6)

The U6-shRNA-GFP AAV (adeno-associated virus) serotype 6 is an important tool in the field of genetic research and therapeutic development. This vector is engineered using AAV serotype 6, which is known for its efficient transduction capabilities, especially in skeletal muscle, liver, and central nervous system tissues. Its design allows for the expression of random shRNAs driven by the U6 promoter. The use of random shRNA sequences is a key feature as it provides a non-targeting control that is extremely valuable in gene knockdown experiments, ensuring that any observed effects can be confidently attributed to the specific knockdown of the target gene and not to off-target effects or introduction of the vector itself. The shRNA sequence is designed to be complementary to the specific messenger RNA (mRNA) of the target gene. After transcription, these shRNAs are processed by the cellular machinery into short interfering RNAs (siRNAs), which direct the RNA-induced silencing complex (RISC) to degrade the target mRNA. The inclusion of a GFP (green fluorescent protein) reporter gene in the viral vector provides a visual marker for transduction efficiency. By expressing GFP, researchers can easily identify and isolate successfully transduced cells using fluorescence microscopy or flow cytometry.